Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients.
<h4>Introduction</h4>Erythropoiesis-Stimulating Agents (ESA) are hypothesized to increase cardiovascular mortality in patients with chronic kidney disease. One of the proposed mechanisms is the elevation of blood pressure (BP) by ESA. Therefore, we aimed to determine whether the use of E...
Guardado en:
Autores principales: | Marit M Suttorp, Tiny Hoekstra, Moshe Mittelman, Ilka Ott, Casper F M Franssen, Friedo W Dekker |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/34409735585944028ae8e302ec2f915c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Erythropoiesis stimulating agents approaches to modulate activity
por: Sinclair AM
Publicado: (2013) -
Dyslipidemia and risk of renal replacement therapy or death in incident pre-dialysis patients
por: Pauline W. M. Voskamp, et al.
Publicado: (2018) -
Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy.
por: Carmel M McVicar, et al.
Publicado: (2010) -
Course of symptoms and health-related quality of life during specialized pre-dialysis care.
por: Moniek C M de Goeij, et al.
Publicado: (2014) -
Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective
por: Derbyshire L, et al.
Publicado: (2013)